Jared Gollob - May 4, 2022 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Medical Officer
Signature
/s/ Bruce N. Jacobs, as Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
May 4, 2022
Transactions value $
$33,740
Form type
4
Date filed
5/4/2022, 09:02 AM
Previous filing
Mar 3, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $13.4K +10.2K +27.4% $1.31* 47.5K May 4, 2022 Direct
transaction KYMR Common Stock Options Exercise $20.4K +9.79K +20.63% $2.08* 57.3K May 4, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -10.2K -25.52% $0.00 29.8K May 4, 2022 Common Stock 10.2K $1.31 Direct F1
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -9.79K -8.24% $0.00 109K May 4, 2022 Common Stock 9.79K $2.08 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.
F2 The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.